Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in New York.
The details of the meetings are as follows:
Cantor Global Healthcare Conference
Format: Fireside Chat and One-on-one MeetingsDate: Wednesday, September 3, 2025Location: New York, NYTime of Fireside Chat Presentation: 9:45 AM ETWebcast link: Availablehere
H.C. Wainwright 27th Annual Global Investment Conference
Format: One-on-one meetingsDate: Tuesday, September 9, 2025Location: New York, NYWebcast link: Pre-recorded fireside chat presentation availablehere
The webcasts of the Cantor and H.C. Wainwright fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website atwww.alxoncology.comunder theEventssection of the Events and Presentations tab. Replays of the webcasts will be archived for up to 90 days following the fireside chat dates.
About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and entered the clinic in a Phase 1 trial in August 2025. More information is available atwww.alxoncology.comand on LinkedIn@ALX Oncology.